10-Q: OraSure Technologies Q2 2026: Revenue Dip, Operating Loss Continues

OraSure Technologies reported a 2% decrease in net revenues for Q2 2026 compared to the prior year, alongside a continued operating loss, though a significant non-cash gain from contingent consideration adjustments improved net income.

Summary

• OraSure Technologies reported net revenues of $30.6 million for the three months ended June 30, 2026, a 2% decrease from $31.2 million in the same period of 2025.
• For the six months ended June 30, 2026, net revenues were $58.6 million, a 4% decrease from $61.2 million in the prior year.
• The company reported an operating income of $5.4 million for Q2 2026, a significant improvement from an operating loss of $18.0 million in Q2 2025, largely due to a $22.6 million non-cash gain from the change in estimated fair value of acquisition-related contingent consideration.
• However, for the six months ended June 30, 2026, the company reported an operating loss of $17.8 million, compared to a $35.8 million operating loss in the same period of 2025.
• Net income for Q2 2026 was $6.2 million, a substantial improvement from a net loss of $19.7 million in Q2 2025.
• For the six months ended June 30, 2026, the net loss was $16.1 million, compared to a $35.7 million net loss in the same period of 2025.
• Cash and cash equivalents decreased to $160.6 million as of June 30, 2026, from $199.3 million as of December 31, 2025.
• The company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements over the next twelve months.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to declining revenues and continued operating losses, despite a significant non-cash gain from contingent consideration adjustments.

Positives

• Achieved operating income of $5.4 million in Q2 2026, a significant turnaround from an operating loss of $18.0 million in Q2 2025.
• Reported net income of $6.2 million in Q2 2026, a substantial improvement from a net loss of $19.7 million in Q2 2025.
• Diagnostics product revenues saw a 1% increase in Q2 2026, driven by higher syphilis sales and the inclusion of SickleSCAN revenues.
• Gross profit margin improved to 43.5% in Q2 2026 from 42.1% in Q2 2025.
• Received FDA clearance in June 2026 for the Colli-PeeDx Urine Collection Kit for use with Roche's tests for STIs.
• Received Emergency Use Authorization (EUA) from the FDA in July 2026 for its second-generation OraQuick Ebola Rapid Antigen Test.
• The company expects existing cash and cash equivalents to be sufficient for the next twelve months.

Negatives

• Net revenues decreased by 2% to $30.6 million in Q2 2026 compared to Q2 2025.
• Net revenues decreased by 4% to $58.6 million for the first six months of 2026 compared to the same period in 2025.
• Operating loss for the first six months of 2026 was $17.8 million, compared to $35.8 million in the prior year.
• Net loss for the first six months of 2026 was $16.1 million, compared to $35.7 million in the prior year.
• Cash and cash equivalents decreased by $38.7 million to $160.6 million as of June 30, 2026.
• Risk Assessment Testing revenues are zero in 2026, as the product line was discontinued.
• COVID-19 Diagnostics revenues decreased by 96% for the first six months of 2026.
• General and administrative expenses increased by 14% in Q2 2026 and 8% for the first six months of 2026, largely due to increased legal and professional fees related to stockholder activism.

Risks

• Failure of distributors or other customers to meet purchase forecasts, historic purchase levels, or minimum purchase requirements.
• Significant customer concentrations that exist or may develop in the future.
• Inability to obtain and comply with necessary regulatory approvals for new products or new indications for existing products.
• Reliance on sole-supply vendors for critical components, which could lead to increased costs and substantial delays.
• Potential patent infringement claims and the availability of licenses to patents or other technology.
• Volatility of the Company's stock price.
• The withdrawal of the CT/NG test submission to the FDA may impact future commercialization timelines and revenue expectations.
• The ongoing litigation with NowDiagnostics, Inc., Jody Berry, and Janean Young, with a trial scheduled for January 17, 2027.

Future Outlook

The company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements over the next twelve months. However, future cash requirements may vary materially due to factors such as strategic acquisitions, R&D progress, clinical testing, litigation costs, capital expenditures, partner relationships, regulatory approvals, stock purchases, patent costs, sales and marketing expansion, market acceptance of new products, competitive developments, and the economic environment.

Management Comments

• The company's management believes its disclosure controls and procedures were effective as of June 30, 2026.
• Management has evaluated the effectiveness of the company's internal control over financial reporting and found no material changes that have affected or are likely to affect it.
• Management believes the outcomes of current legal actions are not expected, individually or in the aggregate, to have a material adverse effect on the Company's future financial position or results of operations.

Industry Context

StockSavvy.ai notes that OraSure Technologies operates in the diagnostics and sample management solutions sector, which is subject to rapid technological advancements, evolving regulatory landscapes (like FDA approvals), and global health trends (e.g., infectious disease outbreaks). The company's performance is influenced by R&D investment, market adoption of new tests, and the competitive environment, including larger players and emerging technologies.

Comparison to Industry Standards

• The company's gross profit margin of 43.5% for Q2 2026 is within a typical range for diagnostic companies, but specific comparisons require detailed industry benchmarks for similar product lines.
• The significant operating loss for the first six months of 2026 ($17.8 million) indicates ongoing investment in growth or challenges in achieving profitability, which is not uncommon for companies in the development and commercialization phase of diagnostic technologies.
• The company's focus on infectious disease testing (HIV, HCV, Ebola, COVID-19) and sample management solutions aligns with broader industry trends towards point-of-care diagnostics and personalized medicine.
• The withdrawal of the CT/NG submission and subsequent need for a new clinical trial highlights the rigorous and often lengthy regulatory pathways in the diagnostics industry, similar to challenges faced by competitors seeking FDA clearance.

Legal Proceedings

• OraSure Technologies filed a complaint against NowDiagnostics, Inc., Jody Berry, and Janean Young on November 14, 2024, alleging misappropriation and misuse of proprietary information and trade secrets, breach of contract, unfair competition, and tortious interference. NowDx filed counterclaims, and a trial is scheduled for January 17, 2027. A preliminary injunction remains in place.

Related Party Transactions

• The Company loaned Sapphiros $0.3 million during the year ended December 31, 2025, due in December 2026.
• The Company recognized $0.1 million and $0.2 million in product and services revenue from an agreement with Sapphiros for assistance in product development during the three and six months ended June 30, 2026, respectively.

Stakeholder Impact

• Shareholders may be impacted by the declining revenues and continued operating losses, although the Q2 2026 net income and operating income show a positive short-term trend.
• Employees may be impacted by ongoing workforce reductions, with completion expected in late 2026 and early 2027.
• Customers may benefit from new product clearances (Colli-PeeDx, OraQuick Ebola 2.0) and the acquisition of SickleSCAN, but potential supply chain risks from sole-source vendors remain.
• Creditors are not directly impacted by immediate financial distress, given the company's cash position, but long-term profitability is key.

Next Steps

• Pursue a future submission for the CT/NG test on the Sherlock platform based on a new clinical trial.
• Ramp up production of the OraQuick Ebola 2.0 Rapid Antigen Test to meet potential demand.
• Continue to evaluate the fair value of assets acquired and liabilities assumed in business combinations.
• The company expects to complete its Q3 2024 Reduction in Workforce by October 2026.
• The company expects to complete its Q1 2026 Reduction in Workforce by February 2027.
• Trial for the NowDiagnostics litigation is scheduled for January 17, 2027.

Key Dates

Recommendation

While the Q2 2026 results show a significant improvement in net income and operating income due to a non-cash gain, the overall trend of declining revenues and continued operating losses for the year-to-date period, coupled with the delay in the CT/NG product submission and ongoing litigation, warrants a cautious 'hold' stance. The company's cash position provides a buffer, but sustained revenue growth and profitability are yet to be demonstrated.

Keywords

Diagnostics, Molecular Diagnostics, Sample Management, HIV, HCV, Sickle Cell, Ebola, FDA